Cargando…

Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas

The PI3K/Akt/mTOR (PAM) axis is constitutively activated in multiple lymphoma subtypes and is a promising therapeutic target. The mTOR inhibitor temsirolimus (TEM) and the immunomodulatory agent lenalidomide (LEN) have overlapping effects within the PAM axis with synergistic potential. This multicen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Major, Ajay, Kline, Justin, Karrison, Theodore G., Fishkin, Paul A. S., Kimball, Amy S., Petrich, Adam M., Nattam, Sreenivasa, Rao, Krishna, Sleckman, Bethany G., Cohen, Kenneth, van Besien, Koen, Rapoport, Aaron P., Smith, Sonali M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2021
Materias:	Article - Non-Hodgkin Lymphoma
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244831/ https://www.ncbi.nlm.nih.gov/pubmed/34320785 http://dx.doi.org/10.3324/haematol.2021.278853

Ejemplares similares

Programmed cell death ligand 1 expression in aggressive pediatric non-Hodgkin lymphomas: frequency, genetic mechanisms, and clinical significance
por: Fisher, Kevin E., et al.
Publicado: (2022)

Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study
por: Ghione, Paola, et al.
Publicado: (2022)

Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results
por: Rai, Shinya, et al.
Publicado: (2022)

Whole-genome profiling of primary cutaneous anaplastic large cell lymphoma
por: Torres, Armando N. Bastidas, et al.
Publicado: (2021)

Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells
por: Galtier, Jean, et al.
Publicado: (2022)

Impact of positron emission tomography - computed tomography status on progression-free survival for relapsed follicular lymphoma patients undergoing autologous stem cell transplantation
por: Eyre, Toby A., et al.
Publicado: (2022)

CCR6 activation links innate immune responses to mucosa-associated lymphoid tissue lymphoma development
por: Korona, Boguslawa, et al.
Publicado: (2022)

Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study
por: Kostakoglu, Lale, et al.
Publicado: (2021)

Follicular lymphoma grade 3B and diffuse large B-cell lymphoma present a histopathological and molecular continuum lacking features of progression/ transformation
por: Koch, Karoline, et al.
Publicado: (2022)

Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study
por: Dourthe, Marie Emilie, et al.
Publicado: (2022)

Humoral immune depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma
por: Bouard, Louise, et al.
Publicado: (2022)

A pilot study of the use of dynamic analysis of cell-free DNA from aqueous humor and vitreous fluid for the diagnosis and treatment monitoring of vitreoretinal lymphomas
por: Wang, Xiaoxiao, et al.
Publicado: (2022)

Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS
por: Wai, Cho Mar Myint, et al.
Publicado: (2022)

Mutational landscape of high-grade B-cell lymphoma with MYC-, BCL2 and/or BCL6 rearrangements characterized by whole-exome sequencing
por: Künstner, Axel, et al.
Publicado: (2021)

Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma
por: Tanaka, Norio, et al.
Publicado: (2022)

Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis
por: Arribas, Alberto J., et al.
Publicado: (2022)

Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study
por: García-Sancho, Alejandro Martín, et al.
Publicado: (2022)

The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease
por: Horna, Pedro, et al.
Publicado: (2022)

In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program
por: Isaev, Keren, et al.
Publicado: (2022)

Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome
por: Veloza, Luis, et al.
Publicado: (2022)

The IL32/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibition
por: Decombis, Salomé, et al.
Publicado: (2022)

Small-molecule SUMO inhibition for biomarker-informed B-cell lymphoma therapy
por: Demel, Uta M., et al.
Publicado: (2022)

Focal structural variants revealed by whole genome sequencing disrupt the histone demethylase KDM4C in B-cell lymphomas
por: López, Cristina, et al.
Publicado: (2022)

Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation
por: Thus, Yvonne J., et al.
Publicado: (2022)

Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high-dose chemotherapy independent of MIPI and complement established high-risk factors
por: Gerdtsson, Anna Sandström, et al.
Publicado: (2022)

Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL)
por: Tucci, Alessandra, et al.
Publicado: (2022)

DUSP22 rearrangement is associated with a distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma
por: Qiu, Lianqun, et al.
Publicado: (2022)

ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study
por: Sibon, David, et al.
Publicado: (2022)

Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma
por: Li, Lingzhi, et al.
Publicado: (2022)

Germline HAVCR2 mutations and their relation to the clinical spectrum of subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis: results from a multicenter study and meta-analysis
por: Moonla, Chatphatai, et al.
Publicado: (2023)

Evidence of cure for extranodal nasal-type natural killer/T-cell lymphoma with current treatment: an analysis of the CLCG database
por: Liu, Xin, et al.
Publicado: (2023)

Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance
por: Barraclough, Allison, et al.
Publicado: (2023)

The Geriatric Prognostic Index: a clinical prediction model for survival of older diffuse large B-cell lymphoma patients treated with standard immunochemotherapy
por: Isaksen, Kathrine T., et al.
Publicado: (2023)

Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients
por: Laracy, Justin C., et al.
Publicado: (2023)

Characterization and clinical impact of the tumor microenvironment in post-transplant aggressive B-cell lymphomas
por: Leivonen, Suvi-Katri, et al.
Publicado: (2023)

Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma
por: Kameda, Takuro, et al.
Publicado: (2023)

Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphoma
por: Song, Joo Y., et al.
Publicado: (2023)

Long non-coding RNA mitophagy and ALK-negative anaplastic lymphoma-associated transcript: a novel regulator of mitophagy in T-cell lymphoma
por: Mularoni, Valentina, et al.
Publicado: (2023)

Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial
por: Ding, Kaiyang, et al.
Publicado: (2023)

Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes
por: Wagner, Charlotte B., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a00b81ajnstqj7s5b0927qpm6c